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Background: Chronic granulomatous disease (CGD) is caused by a malfunctioning
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex in phagocytes,
leading to impaired bacterial and fungal killing and hyperinflammation.
Objective: To characterize macrophage subsets and cytokine/chemokine signaling
loops involved in CGD tissue hyperinflammation.
Methods: Cytokine/chemokine production and surface marker expression were
analyzed in inflamed tissue of four CGD patients and compared to cytokine/chemokine
released by CGD macrophages upon priming to different macrophage subpopulations.
Furthermore, the re-priming capacity of CGD pro-inflammatory M1 to M2a anti-
inflammatory macrophages was evaluated.
Results: In human CGD inflammatory tissue, IL-18 and IFN-γ were detected in
significant quantity. Immunofluorescence analysis identified macrophages as one source
of IL-18 in inflamed tissue. In vitro, CGD macrophages could be primed and re-primed
into all inflammatory/anti-inflammatory macrophage subpopulations. IL-18 was also
released by M1 CGD and control macrophages.
Conclusion: CGD pro-inflammatory M1 macrophages remain M1 primed in vivo. As
CGD M1 macrophages can be re-primed to anti-inflammatory M2a phenotype in vitro,
macrophages are kept in M1 state in vivo by a persistent pro-inflammatory environment.
Our results suggest a paracrine signaling loop between M1 macrophage derived IL-18
and non-macrophage derived IFN-γ maintaining macrophage pro-inflammatory activity
in CGD tissue.
Keywords: chronic granulomatous disease, hyperinflammation, macrophage priming, macrophage re-priming,
IL-18/IFN-γ loop
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INTRODUCTION
Chronic granulomatous disease (CGD) is a primary
immunodeficiency caused by defects of the phagocyte
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
and concomitantly impaired generation of reactive oxygen
species (ROS) (1, 2). CGD patients suffer from a predisposition
to recurrent life-threatening fungal and bacterial infections, as
pathogens can be engulfed by CGD phagocytes, but cells are
unable to kill phagocytosed pathogens (3, 4). Pathogen-loaded
CGD phagocytes form a barrier to antibodies and extracellularly
acting antibiotics. The resulting infectious foci stimulate
granuloma formation, partly through release and persistence
of chemoattractants, which require oxygen metabolism for
their degradation (5, 6). Another important manifestation is an
enhanced and persistent inflammatory response. CGD patients
may have concomitant autoimmune complications (7, 8), such as
colitis (8–10). Up to 50% of CGD patients have gastrointestinal
(GI) manifestations of their disease that include colitis and
gastric outlet obstruction (9, 11, 12). The pathophysiology of
CGD hyperinflammation is unclear. CGD patients present
an increase of Th17 cells and Th17-derived cytokines (13),
as well as high levels of serum antibodies to antigens present
on gastrointestinal (GI)-tract associated microbes (14). Both
increased pro-inflammatory activity and defective apoptosis
of polymorphonuclear leukocytes (PMNs) have been linked to
granuloma formation in X-CGD patients (15). Increased caspase
1 activation and IL-1β were reported in CGD macrophages after
Nod-Like Receptor Pyrin 3 (NLRP3) inflammasome stimulation
(16). Stimulation of CGD whole blood with Aspergillus fumigatus
led to increased release of TNFα, IL-6, and IL-10, suggesting
a dysregulation of pro-inflammatory and anti-inflammatory
response (17). Clinical improvements of colitis in CGD patients
were reported upon IL-1 blockage (18) and upon thalidomide
treatment which led to suppression of TNF-α induced NFκB
activation, a decreased bowel inflammation characteristic and
reduced serum cytokines (19). Patients with CGD also present
inflammatory conditions in the absence of detectable infections
(20). Death of a CGD patient can be caused by an infection
and/or by an inflammatory disease. Brown and colleagues
reported on four CGD patients, of which two died during the
course of the study. One patient died due to an infection and
the other due to an overwhelming and irreversible pulmonary
inflammation with no detectable infection (21). Macrophages
play a pivotal role in tissue homeostasis and in the inflammatory
process. Classically, macrophages and dendritic cells were
seen to derive from a Macrophage Dendritic Cell Precursor
(MDP) upon differentiation of monocytes in the steady state
Abbreviations: CGD, chronic granulomatous disease; DAPI, 4′,6-Diamidin-
2-phenylindol; DNA, deoxyribonucleic acid; EDTA, ethylenediaminetetraacetic
acid; GI, gastrointestinal; HSCT, hematopoietic stem cell transplantation; LPS,
lipopolysaccharide; MNCs, mononuclear cells; NADPH, nicotinamide adenine
dinucleotide phosphate; NET, neutrophil extracellular trap; NLRP3, Nod-Like
Receptor Pyrin 3; PBS, phosphate buffered saline; PFA, paraformaldehyde; PMA,
phorbol 12-myristate 13-acetate; PMNs, polymorphonuclear leukocytes; PPAR-
γ, proliferator-activated receptor γ; PS, phosphatidylserine; ROS, reactive oxygen
species; SEM, standard error of the mean; WT, wild type.
(22). Mouse studies revealed that tissue macrophages derive
from embryonic precursors which already before birth seed the
tissue and which in adult tissue maintain their number by self-
renewal (23). The corresponding hypothesis that human tissue
macrophages emerge from embryonic precursors is reasonable,
but difficult to test. Most reports on mouse macrophages are
conducted with bone marrow-derived macrophages (BMDM)
and most human macrophage work was carried out with blood
monocyte-derived macrophages.
Macrophages show high plasticity. Responding to stimulation,
macrophages can shift their activity in a process termed
polarization or priming. The distinction of mouse macrophages
between classically activated (IFN-γ and LPS) M1 macrophages
with pro-inflammatory phenotype and with pathogen-killing
abilities, and alternatively activated M2 macrophages promoting
cell proliferation and tissue repair (24) goes back to the
initial work of Mills et al. (25). A further subdivision of
M2 macrophages into M2a, M2b, and M2c was described by
Mantovani et al. (26).M2amacrophages polarized upon exposure
to IL-4 and dexamethasone (27) and M2b macrophages primed
by immune complexes and LPS (28), were described to possess
immunoregulatory functions and to drive type II responses,
whereas exposure of macrophages to M-CSF and IL-10 (29)
prime toM2c macrophages involved in immune suppression and
tissue remodeling (26).
In healthy individuals, termination of a bacterial or a
fungal infection is initiated by granulocytic ROS production
triggering intra- or extracellular pathogen killing (30), as well
as granulocytic cell death, leading to exposure of oxidized
phosphatidylserine (PS) membrane lipids on cell debris (31).
Macrophages recognize oxidized PS and efferocytose the cell
debris, followed by induced IL-4 expression, secretion and self-
stimulation of macrophages and termination of inflammation
(32). In murine CGD models, an impaired efferocytosis
and IL-4 expression were noted, together with an impaired
invariant natural killer T (iNKT) cells activation, resulting in
persistent M1 pro-inflammatory status of macrophages (32,
33). Treatment of CGD mice or ex vivo treatment of human
macrophages with proliferator-activated receptor γ (PPAR-γ)
agonists induced mitochondrial superoxide production and
restoration of efferocytosis, thus bypassing an impaired NADPH
oxidase activity (34, 35).
Efferocytosis of granulocytic debris and IL-4 self-stimulation
induces a shift in macrophage priming from pro-inflammatory
M1 into anti-inflammatory M2a status. Macrophages of X-CGD
mice were reported as primarily M1-primed, whilst wild type
(WT) macrophages were M2a-primed (32, 33). As the reason of
the persistent pro-inflammatory state in CGD is only partially
known, we set out to characterize primary-derived inflamedCGD
tissue samples as well as ex vivo priming of CGD macrophages.
MATERIALS AND METHODS
Patients
Heparinized blood samples and biopsies were obtained in
compliance with local ethical requirements (ethical approval
number KEK-ZH-Nr 2015-0135 and BASEC-Nr. PB_2016-0220)
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after obtaining written informed consent from healthy controls
and CGD patients. Only blood samples of diagnosed CGD
patients without residual NADPH oxidase activity who were not
under steroid or IFN-γ treatment, and whowere in a stable steady
state without ongoing inflammation, were analyzed.
Patient 1 (acute dental abscess, 48 h) was a 6-year-old boy,
diagnosed with X-CGD (CYBB c.632T > G) by molecular
biology analysis (Sanquin, Amsterdam, The Netherlands)
without detectable residual ROS formation by phagocytes in
dihydrorhodamine (DHR) and nitroblue tetrazolium (NBT)
tests. The patient presented with a dental abscess 48 h after
minor trauma. At the time of the analysis, patient was
otherwise asymptomatic, without clinical signs of inflammation
at other body sites. He was under prophylactic treatment with
itraconazole and co-trimoxazole, but did not receive IFN-γ
or corticosteroids. Microbiological analysis of the abscess was
not performed.
Patient 2 (subcutaneous abscess right side of the neck, 2
weeks) was a 16-year-old male diagnosed with p47phox-deficient
CGD (NCF1, homozygous GT dinucleotide deletion in exon
2) by molecular biology analysis (Sanquin, Amsterdam, The
Netherlands). Four percent of the patient’s phagocytes possessed
residual ROS activity (DHR assay). In the DHR assay, the shift
in fluorescence intensity (1GeoMean MFI = GeoMean of mean
fluorescent intensity (MFI) of PMA stimulated DHR-positive
cells minus GeoMean MFI of unstimulated cells) of patient cells
corresponded to 1.1% of the shift observed in a healthy control
indicating a low level of residual cellular ROS production. The
subcutaneous abscess at the right side of the neck was surgically
drained (no microorganisms could be identified), followed by
a course of antibiotic treatment, in addition to the standard
prophylaxis with itraconazole and co-trimoxazole.
Patient 3 (sub-muscular thoracic abscess, 4 weeks), was a 27-
year-old male, diagnosed with X-CGD at the age of 5 (CYBB).
Patient presented with sub-muscular abscess of the thoracic wall,
which was not connected with intra-abdominal or intra-thoracic
walls. Histologically, the abscess was described as a mixed
extended chronic granulizing and florid granulocytic, necrotizing
and giant cell inflammation around few fungal elements.
Microbiological analysis identified Aspergillus fumigatus. At
the time of the analysis, patient was treated with tazobactam
and voriconazole.
Patient 4 (submandibular lymph node abscess, 6 weeks) was
a 1-year-old girl with AR CGD (NCF1 delta GT). She was
diagnosed with a bilateral submandibular fistulising lymph node
abscess. Surgical drainage revealed the presence of Burkholderia
cepacia. DHR test showed 17–25% of cells with residual NADPH
oxidase function on a low level, as the shift of DHR-positive
cells (1GeoMean MFI) corresponded to only 1.9% of the shift
observed in healthy control cells.
A deep frozen control lymph node sample of a non-CGD
patient presenting recurrent lymph node hyperplasia was kindly
provided by the tissue biobank of the Institute of Pathology and
Molecular Pathology of University Hospital Zürich.
Flow Cytometry
Tissues were transported and homogenized as described
in the Materials and Methods section “cytokine and
chemokine analysis.” To avoid sampling errors, >50%
of tissue was processed for flow cytometry analysis and
cytokine quantification. Tissue-derived cells and ex vivo-primed
macrophages were blocked with FcR blocking reagent (MACS,
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and
stained with the antibodies as follows. Anti-human CD14
PC7 (clone RMO52), anti-human CD209 (DC-SIGN)-PE
(clone AZND1), anti-human CD14 PC7 (clone RMO52) were
from Beckman Coulter International S.A., Nyon, Switzerland.
Anti-human CD15 V500 (HI98), anti-human CD57 FITC
(HNK-1), anti-human CD56 PE (B159 RUO), anti-human
CD8 V450 (RPA-T8) and anti-human CD8 V450 (RPA-T8)
were from BD Bioscience, Eysins, Switzerland. Anti-human
CD3 Alexa Fluor R© 700 (UCHT1), anti-human Vα24Jα18
TCR PE-Cyanine7 (6B11), and anti-human CD206 (MMR)
eFluor R© 450 (clone 19.2) were from eBioscience, Eysins,
Switzerland. Anti-human CD4 PerCP (OKT4), anti-human
CD19 Brilliant Violet 605 (HIB19), anti-human CD163
PerCP/Cy 5.5 (clone GHI/61) anti-human CD86 Brilliant
Violet 605TM (clone IT2.2) were from BioLegend, Lucerna-
Chem AG, Luzern, Switzerland. Anti-human Mer APC (clone
125518) were from R&D Systems, Bio Techne AG, Zug,
Switzerland. Cells were washed, fixed with 2% formaldehyde
in PBS, measured by GalliosTM flow cytometer and analyzed
by Kaluza software (Beckman Coulter International S.A.,
Nyon, Switzerland).
Cytokine and Chemokine Analysis
Volume of pus samples were determined and diluted to
separate cells from supernatant by centrifugation. Solid tissues
were kept in PBS on ice for up to 1 h until >50% of
samples were weighed and homogenized with a syringe
piston on a Petri-dish. Remaining tissue was removed by
filtration (70µm cell strainer). For flow cytometry analysis,
cells were separated from supernatant by centrifugation.
Supernatant was stored at−80◦C until cytokine quantification in
duplicates by 18plex Immunoassay (Cat. No. EPX180-12165-901,
eBioscience, Thermo Fisher Scientific AG, Basel, Switzerland)
and MILLIPLEX R© MAP KIT (Cat. No. HCYTOMAG-60K,
MILLIPORE, Merck AG, Zug, Switzerland) according to
manufacturers’ instructions for quantification of G-CSF, GM-
CSF, IFN-γ, MDC, TNFα, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-
9, IL-10, IL-12p70, IL-13, IL-17A, IL-18, IL-21, IL-22, IL-23,
and IL-27. Cytokines concentrations are expressed in ng/ml of
undiluted tissue.
Immunofluorescence
Paraffin-embedded slides were dewaxed and stained with
rabbit anti-human IL-18 (LS-C313164, Lifespan Biosciences,
LabForce AG, Muttenz, Switzerland) and mouse anti-human
CD68 (clone 514H12, Novocastra Laboratories Ltd., Newcastle
upon Tyne, UK), followed by donkey anti-rabbit FITC (711-
095-152, Jackson ImmunoResearch Ltd., MILAN ANALYTICA
AG, Rheinfelden, Switzerland), donkey anti-mouse Cy3 (715-
165-150, Jackson ImmunoResearch Ltd., MILAN ANALYTICA
AG, Rheinfelden, Switzerland) followed by mouse anti-FITC
Alexa488 (200-542-037, Jackson ImmunoResearch Ltd., MILAN
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ANALYTICA AG, Rheinfelden, Switzerland) and 4′,6-Diamidin-
2-phenylindol (DAPI) staining conducted by Sophistolab AG
(Muttenz, Switzerland).
Slides were analyzed by confocal microscopy (model TCD
SP8, Leica Geosystems Holdings AG, Glattbrugg, Switzerland)
with original magnification x40. Acquired images were processed
using ImageJ (36).
Immunohistochemistry
Immunohistochemistry was perfomed by Sophistolab AG
(Muttenz, Switzerland) on Leica BondMax instruments using
Refine HRP-Kits (Leica DS98000, Leica Microsystems Newcastle
Ltd., Newcastle upon Tyne, UK) according to manufacturer’s
instructions. Paraffin-slides were dewaxed, penetrated, and
stained with rabbit anti-human IFN-γ (LS-B7487, Lifespan
Biosciences, LabForce AG, Muttenz, Switzerland), visualized by
HRP Refine Kit (DS9800, Leica Microsystems GmbH, Wetzlar,
Germany). Images were then analyzed with a bright-field
microscope (Axiovert S100TV, Carl Zeiss Vision Swiss AG,
Feldbach, Switzerland).
Monocyte Isolation and Differentiation to
Macrophages
Monocytes were isolated from mononuclear cells after FICOLL
(Ficoll-Paque PLUS, GEHealthcare AG, Glattbrugg, Switzerland)
density gradient centrifugation, followed by magnetic bead-
based positive selection (CD14 human microbeads, Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) according to
manufacturer’s description. Cells were cultured (2.8 × 105
cells/well) in PRIMARIA 24 wells plate (Becton Dickinson AG,
Allschwil, Switzerland) in RPMI supplemented with Octaplas
SD 10% (Octapharma AG, Lachen, Switzerland), 2mM sodium
pyruvate, 2mM L-glutamine, 10mM HEPES, and M-CSF
100 ng/ml (research grade, MACS, Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany) for 7 days.
24h Priming of Macrophages
Macrophages were either kept in culture for 24 h in a
fresh differentiation medium (M0 macrophages), or stimulated
with IFN-γ (50 ng/ml, e-Bioscience, Thermo Fisher Scientific
AG, Basel, Switzerland) and LPS (10 ng/ml, Sigma-Aldrich
GmbH, Buchs, Switzerland) for M1 priming, IL-4 (20 ng/ml,
ProSpec-Tany TechnoGene Ltd., Ness Ziona, Israel) for M2a,
in wells pre-coated with human IgG (5 µg/cm2, Sigma-
Aldrich GmbH, Buchs, Switzerland), and supplemented with
LPS (100 ng/ml, Sigma-Aldrich GmbH, Buchs, Switzerland) for
M2b, or supplemented with IL-10 (100 ng/ml, Sanofi Genzyme,
Vernier, Switzerland) and M-CSF (100 ng/ml, MACS, Miltenyi
Biotec, GmbH, Bergisch Gladbach, Germany) for M2c. For
cytokine/chemokine analysis, supernatants were centrifuged,
and aliquots were stored at −80◦C. After 24 h of stimulation,
macrophages were detached with EDTA and analyzed by flow
cytometry analysis.
Macrophage Re-priming
Supernatants from 24 h un-primed M0, or from 24 h M1,
M2a, and M2c primed macrophages were removed, cells
were washed with PBS without detachment, and re-primed
for 72 h by incubation with priming stimuli (described
in 24 h Priming of Macrophages). Ninty six hours after
initial priming corresponding to 72 h after repriming,
supernatants were centrifuged and stored at −80◦C for
cytokine/chemokine quantification.
Statistical Analysis
Statistical analysis was performed as indicated by ANOVA with
post hoc Bonferroni correction using SPSS (Version 22, IBM), and
graphs were prepared using GraphPad Prism Software (Version
5.0a; GraphPad Software, La Jolla, California, USA).
RESULTS
Characterization of Cellular Infiltrates in
Acute vs. Chronically Inflamed Tissue
Biopsies of inflammatory lesions of four CGD patients were
analyzed: (1) pus from a gingival abscess present for 48 h (no
culture performed), and three samples of chronic inflammatory
lesions, which were (2) pus from a subcutaneous abscess of the
neck present for 2 weeks (no microorganisms found), (3) tissue
sample from a sub-muscular thoracic abscess inflamed for 4
weeks (Aspergillus fumigatus cultured), and (4) a lymph node of
the neck with inflammation present for 6 weeks (Burkholderia
cepacia cultured).
In the extracellular fraction of tissue samples, levels of
signaling molecules were quantified (Figure 1) and cellular
composition of isolated cell population was analyzed (Table S1).
While granulocytes were the predominant cell type in the
acute gingival abscess (87.6% CD15+ cells), in chronically
inflamed neck abscess material and thoracic tissue, granulocytes
were underrepresented (0.2 and 0.7% CD15+ cells, respectively).
CD14+ macrophages were noted in moderate amounts in
chronically inflamed thoracic tissue (9.9%), whilst acute gingival
abscess and neck abscess contained only 0.4 and 0.7% CD14+
cells, respectively. iNKT cells (CD3, CD56, and vαJ18CD56+)
were the predominating cell type (83.9%) in 2 weeks old
neck abscess, whereas they accounted for only 3.4% of cells
in 4 weeks old thoracic inflammation, and 0.1% in acute
gingival abscess. NK cells (CD57+) accounted for only 0.2 and
2.4% in chronically inflamed thoracic and neck samples, and
were undetectable in acute gingival abscess. Cytotoxic T cells
(CD3/CD8+) were present in thoracic tissue (9.8%) and, in low
numbers, in the acute gingival abscess (0.3%), and undetectable
in the neck abscess. Helper T cells (CD3/CD4+) were found
in low numbers in neck abscess (1.4%), but were absent in
thoracic tissue or gingival abscess. Thoracic tissue presented
37.4%CD3(+)CD4(–)CD8(–) double negative T cells (21), which
were negative for other analyzed surface markers. B cells were
hardly detectable in thoracic tissue (0.1%), and absent in all
other tissues.
Quantification of Released
Cytokines/Chemokines
Cytokine/chemokine pattern in acute inflammation (48 h pus)
with high amounts of IL-6, TNFα, and IL-22, differed
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FIGURE 1 | Quantification of signaling molecules in inflamed primary derived human CGD material of (A) lymph node of the neck present since 6 weeks, (B)
sub-muscular thoracic abscess inflamed since 4 weeks, (C) pus from subcutaneous abscess of the neck present since 2 weeks, (D) puss from gingival abscess
present since 48 h. In the supernatant of primary derived smashed tissues signaling molecules were quantified by Multiplex immunoassay. Results are given in pg/ml
of local undiluted concentrations. Tissue types and duration of inflammation at the time of the analysis are indicated.
significantly from that found in chronically inflamed tissues.
IL-22 and TNFα were detectable only in low quantity in
chronically inflamed tissue. IL-6 was detectable in all samples,
but in chronically inflamed samples at maximum 10% of the
quantity found in pus of acute inflamed tissue containing high
percentage of neutrophils. In chronic inflammation in lymph
node and thoracic tissue, IL-18 was the predominant cytokine
identified. IFN-γwas detectable in all tissues inmoderate amount
(Figure 1).
Cytokine and chemokine levels detected in inflamed lymph
node and in other inflamed tissues were significantly higher
than those quantified in a control lymph node (Figure S1). IFN-
γ and IL-18 levels in inflamed lymph node tissue exceeded
the levels of control tissue by factor 2.6 and 6.3. Of note,
local cytokine/chemokine concentrations were not reflected by
serum levels: inflamed lymph node tissue expressed several
signaling molecules at very low levels (G-CSF, GM-CSF, IL-4,
IL-22, MDC), while high levels of IL-18, IL-1β, IFN-γ, IL-6,
and TNFα were found (Figure 1A). At the same time, in serum
only IFN-γ, TNFα, and IL-18 could be quantified with serum
levels ranging between 4.0 and 9.8% of the corresponding local
tissue levels. Locally, IL-18 and IFN-γ were present in inflamed
lymph node tissue at the levels of 28,328 and 5,081 ng/ml,
whilst only low amounts of 227 and 98 ng/ml were detectable
in serum.
Analysis of Chronically Inflamed Lymph
Node Tissue
Immunohistochemically, IFN-γ was weakly detectable lining
up along necrotic tissue and presenting within local clustered
structures (Figure 2B). The exact source of IFN-γ is a matter
of further investigation. IL-18 staining revealed individual cells,
which were clearly positive for IL-18, which is also called IFN-
γ-inducing factor. Macrophages were partially positive for IL-18
in the non-necrotic areas and in the germinal cells of the lymph
nodes. In contrast, the macrophages forming large granulomas
around necrotic tissue were mostly negative for IL-18. Double
immunofluorescence staining of inflamed lymph node tissue
identified CD68-positive macrophages as one source of IL-18
expression (Figure 2A; Figures S3A–C). Representative pictures
of inflamed CGD lymph node tissue upon hematoxylin and eosin
(H&E) staining are provided in Figure S2.
CGD Macrophages Can Acquire M1, M2a,
M2b, or M2c Priming Activity
To distinguish between a potential priming defect or bias in CGD
macrophages, and a persistent paracrine IL-18/IFN-γ signaling-
loop that would keep macrophages in a pro-inflammatory state,
the priming capacity of CGD macrophages was analyzed. Blood-
derived macrophages of healthy controls and of CGD patients
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FIGURE 2 | Detection of IL-18 and IFN-γ in inflamed lymph node tissue of a CGD patient at 6 weeks of inflammation. (A) Merged DAPI (blue), IL-18 (green)/CD68
(red) double immunofluorescence staining. IL-18 signal (FITC, Alexa488) colocalized with CD68 (Cy3) on tissue macrophages. Single stainings are in Figure S1. (B)
Immunohistochemical detection of IFN-γ.
TABLE 1 | Surface marker presentation of CGD macrophages compared to control upon ex vivo priming for 24 h.
Surface marker M0 M1 M2a M2b M2c
CD86 CGD 12.3 ± 1.2
CTL 13.0 ± 1.1
CGD 25.9 ± 2.5
CTL 25.9 ± 1.5
CGD 23.1 ± 1.9
CTL 23.6 ± 2.5
CGD 14.2 ± 0.7
CTL 14.0 ± 1.3
CGD 11.8 ± 1.0
CTL 11.6 ± 0.9
CD209 CGD 6.2 ± 1.8
CTL 10.6 ± 0.8
CGD 11.1 ± 3.0
CTL 12.5 ± 2.2
CGD 35.4 ± 5.4
CTL 37.3 ± 7.0
CGD 8.9 ± 1.6
CTL 10.9 ± 2.1
CGD 9.6 ± 2.0
CTL 11.0 ± 1.1
CD206 CGD 34.4 ± 2.9
CTL 29.8 ± 4.9
CGD 32.3 ± 2.7
CTL 27.3 ± 4.8
CGD 63.3 ± 5.0
CTL 62.2 ± 4.9
CGD 19.3 ± 1.2
CTL 18.9 ± 5.0
CGD 38.0 ± 4.1
CTL 29.8 ± 3.9
Mer CGD 105.9 ± 9.1
CTL 129.9 ± 17.9
CGD 58.7 ± 5.9
CTL 52. 6 ± 12.4
CGD 61.2 ± 4.7
CTL 76.2 ± 11.2
CGD 19.1 ± 0.5
CTL 23.8 ± 4.8
CGD 106.4 ± 16.3*
CTL 136.6 ± 10.8*
CD163 CGD 12.1 ± 1.7
CTL 15.6 ± 2.0
CGD 7.2 ± 2.4
CTL 8.6 ± 0.6
CGD 9.2 ± 3.6
CTL 10.4 ± 0.3
CGD 3.3 ± 0.6
CTL 3.6 ± 0.5
CGD 26.1 ± 4.9
CTL 28.6 ± 3.8
Blood monocyte-derived macrophages of CGD patients and healthy controls were primed to macrophage subpopulations for 24 h and analyzed by flow cytometry. Surface marker
presentation is expressed as geomean of mean fluorescence intensities of gated positive populations ± SEM. N = 4, *p < 0.05 (bold).
without residual ROS production were either left unstimulated
(M0) or were primed to M1, M2a, M2b, or M2c activity. Twenty
four hours post priming, obtained macrophage populations were
analyzed for surface marker presentation (Table 1; Figure S4)
and cytokine release (Table 2; Figure S5).
Unprimed macrophages showed only receptor tyrosine-
protein kinase Mer (EC:2.7.10.1) expression and were negative
for CD163. M1-primed macrophages showed high expression of
CD86 and were CD206-/CD209-. CD206 and CD209 expression
is characteristic for M2a, and CD163 expression is characteristic
for M2c primed macrophages. None of the analyzed surface
markers were presented by ex vivo M2b primed macrophages.
Statistically significant differences in surface marker presentation
of CGD vs. control macrophages were only observed for Mer
presentation in M2c macrophages (Table 1).
In M1-primed macrophages, high levels of IL-4, IL-5, IL-
6, IL-12p70, IL-13, IL-18, IL-22, and TNFα were detected, of
which IL-12p70, IL-13, IL-18, and IL-22 were characteristic for
this cell population. M2a-primed macrophages released MDC
and GM-CSF in significant quantities, of which MDC was
only released by M2a macrophages. M2b macrophages were
positive for IL-4, IL-5, IL-6, and TNFα, but in contrast to M1
macrophages which also expressed these cytokines, were negative
for IL-12p70, IL-13, IL-18, and IL-22. M2b-primed macrophages
released only low amounts of MDC, which was synthesized
by M2a-primed macrophages. The release of G-CSF was only
observed in M2b macrophages. Of note, none of the cytokine
levels derived from M2c-primed macrophages exceeded those
of unprimed M0 macrophages. Interestingly, ex vivo priming
of macrophages was not accompanied by induction of IFN-
γ secretion (Table 2; Figure S5). IFN-γ quantification in M1-
primed macrophages was not informative, as it was added to cell
culture for M1 priming.
Statistically significant differences in the supernatant cytokine
and chemokine levels between CGD and control macrophages
were not seen for most of the molecules analyzed, except for
IL-6 in M1, MDC in M1 and G-CSF in M2b with CGD levels
exceeding controls (Table 2). Taken together, we conclude that
an obvious inherent priming defect in CGD macrophages was
not observed.
Macrophage Re-priming as Passive
Reaction to Their Microenvironment
To evaluate the macrophage re-priming capacity, CGD and
control macrophages were primed first for 24 h to pro-
inflammatory M1, followed by 72 h in stimulus-free medium
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TABLE 2 | Cytokine/chemokine secretion of CGD macrophages compared to control upon 24 h priming.
Cytokine M0 M1 M2a M2b M2c
IL-18 CGD 710.2 ± 150.1
CTL 646.8 ± 79.4
CGD 4,447.6 ± 241.1
CTL 4,464.2 ± 250.2
CGD 709.2 ± 125.0
CTL 840.6 ± 117.5
CGD 708. 5 ± 62.0
CTL 931.4 ± 145.5
CGD 658.4 ± 101.6
CTL 719.9 ± 97.1
IL-12p70 CGD 72.9 ± 72.9
CTL 0.00 ± 0.0
CGD 747.9 ± 173.6
CTL 978.7 ± 275.3
CGD 6.3 ± 6.3
CTL 90.8 ± 27.3
CGD 11.4 ± 7.9
CTL 2.3 ± 1.4
CGD 0.0 ± 0.0
CTL 0.2 ± 0.2
IL-13 CGD 48.5 ± 33.0
CTL 8.8 ± 8.8
CGD 182.3 ± 24.8
CTL 186.4 ± 29.0
CGD 47.3 ± 31.5
CTL 81.7 ± 30.2
CGD 17.1 ± 17.1
CTL 25.1 ± 25.1
CGD 25.1 ± 25.1
CTL 20.1 ± 20.1
IL-22 CGD 1,688.1 ± 1688.1
CTL 0.0 ± 0.0
CGD 2,995.6 ± 1,002.7
CTL 1,456.8 ± 650. 4
CGD 0.0 ± 0.0
CTL 89.7 ± 89.7
CGD 29.3 ± 29.3
CTL 140.3 ± 140.3
CGD 533.8 ± 234.2
CTL 841.4 ± 408.4
IFN-γ CGD 295.6 ± 189.3
CTL 126.2 ± 10.3
CGD n.d.
CTL n.d.
CGD 250.3 ± 84.3
CTL 250.3 ± 31.8
CGD 196.4 ± 10.4
CTL 206.9 ± 36.0
CGD 130.5 ± 21.7
CTL 155.9 ± 15.6
IL-6 CGD 3,540.2 ± 1942.3
CTL 2,163.3 ± 757.6
CGD 23,594.9 ± 2,157.9*
CTL 16,522.7 ± 2,333.0*
CGD 2,177.5 ± 1,275.8
CTL 921.3± 402.1
CGD 16,000.2 ± 3,064.7
CTL 18,429.2 ± 2,870.6
CGD 1,189.2 ± 397.8
CTL 995.6 ± 419.0
TNFα CGD 594.7 ± 272.7
CTL 592.7 ± 207.8
CGD 19,227.8 ± 4,476.1
CTL 27,435.5 ± 9,340.2
CGD 1,052.4 ± 307.5
CTL 1,242.0 ± 136.7
CGD 24,135.0 ± 7,174.5
CTL 36,090.4 ± 12,023.0
CGD 114.2 ± 29.4
CTL 161.0 ± 6.3
IL-5 CGD 168.5 ± 128.4
CTL 592.7 ± 207.8
CGD 19,227.8 ± 4,476.1
CTL 27,435.5 ± 9,340.2
CGD 1,052.4 ± 307.5
CTL 1,242.0 ± 136.7
CGD 24,135.0 ± 7,174.6
CTL 36,090.4 ± 12,023.0
CGD 114.2 ± 29.4
CTL 161.0 ± 6.3
IL-4 CGD 326.2 ± 270.8
CTL 36.7 ± 36.7
CGD 903.1 ±32.6
CTL 900.6 ± 22.6
CGD n.d.
CTL n.d.
CGD 565.3 ± 119.3
CTL 759.2 ±127.4
CGD 9.4 ± 9.4
CTL 73.3 ± 42.5
MDC CGD 3,251.1 ± 900.5
CTL 3,647.2 ± 1,107.1
CGD 6,458.5 ± 935.9*
CTL 3,237.7 ± 991.8*
CGD 16,608.2 ± 873.5
CTL 13,977.8 ± 1,472.6
CGD 4,286.1 ±681.6
CTL 1,617.5 ± 573.5
CGD 3,545. 2 ± 1,657.2
CTL 1,963.8 ± 675.7
GM-CSF CGD 1,116.6 ± 830.5
CTL 405.2 ± 211.4
CGD 1,981.0 ± 133.9
CTL 1,981.2 ± 127.9
CGD 7,838.4 ± 351.8
CTL 8,907.1 ± 609.3
CGD 9,012.3 ± 2,624.1
CTL 12,715.1 ± 4,332.3
CGD 188.5 ± 188.5
CTL 423.1 ± 284.7
G-CSF CGD 16.8 ± 2.6
CTL 10.6 ± 3.0
CGD 37.6 ± 9.0
CTL 32.0 ± 4.8
CGD 13.8 ± 4.3
CTL 11.4 ± 2.6
CGD 887.8 ± 329.5*
CTL 571.9 ±103.1*
CGD 16.7 ± 7.2
CTL 11.3 ± 2.6
IL-1β CGD 176.5 ± 68.9
CTL 103.6 ± 28.6
CGD 263.4 ± 22.5
CTL 227.0 ± 25.5
CGD 145.7 ± 22.4
CTL 85.6 ± 26.7
CGD 452.2 ± 178.1
CTL 415.8 ± 105.4
CGD 124.8 ± 16.9
CTL 91.8 ± 27.3
Blood monocyte-derived macrophages of CGD patients and healthy controls were primed (24 h), and cytokine/chemokine concentrations were quantified in cell culture supernatants.
Concentrations are expressed in pg/ml of undiluted tissue as mean ± SEM; N = 4. n.d., not analyzed as it was added to cell culture medium. *p < 0.05 (bold).
FIGURE 3 | CGD and control macrophage derived cytokines/chemokines upon re-priming (72 h) of M1 primed (24 h) macrophages. Macrophages of CGD patients
and of controls were left unstimulated (24 + 72 h) (M0M0), or were primed (24 h), followed by withdrawal of stimulus (M1M0), or by re-priming for 72 h (M1M1;
M2aM2a; M2cM2c; M1M2a; M1M2c). Released cytokines/chemokines of (A) IL-18, (B) MDC and (C) GM-CSF were quantified after 24 +72 h. N = 3, empty =
control, striped = CGD.
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(M1M0) or with medium supplemented with stimuli inducing
M2a (M1M2a) or M2c (M1M2c) re-priming followed by
quantification of cytokine and chemokine release. Macrophages
left unstimulated (M0M0) or exposed to M2a (M2aM2a) or M2c
(M2cM2c) stimuli for 24 + 72 h served as controls (Figure 3;
Figure S4). Upon 72 h re-priming of in vitro generated CGD
M1 macrophages, absolute cytokine and chemokine levels of
all cytokines declined, while cytokine and chemokine patterns
of individual populations remained constant. When 24 + 72 h
stimulated with M1-inducing agents, CGD and control M1M1
macrophages secreted high levels of IL-18, IL-12p70, IL-13,
IL-6, and low levels of G-CSF, IL-1β, IL-5, and IL-4. When
stimulated with M2a-inducing agents, secretion of MDC and
GM-CSF remained high at 24 + 72 h, corresponding to the
pattern at 24 h. When stimulated with M2c-inducing agents,
all cytokines released by macrophages remained on low levels,
compared to levels released by other macrophage populations.
No statistically significant differences between healthy control
and CGDmacrophages were observed in this experimental series
(Figure S6) and both, healthy control and CGDM1macrophages
could be re-primed to anti-inflammatory M2a phenotype by a
shift to M2a stimulus for 72 h (M1M2a), judged by GM-CSF
level (Figure 3C).
Interestingly, all cytokine levels which were secreted by
macrophages upon 24 h ofM1 priming, including IL-18, dropped
after 72 h of incubation in the absence of stimulation (Figure S4),
suggesting that the absence of continuous stimulation leads to
conversion into a silent M0 macrophage subpopulation. Our
results suggest that the presence of IL-18 releasing macrophages
in chronically inflamed CGD lymph node tissue is most likely
caused by a local pro-inflammatory microenvironment.
DISCUSSION
Chronic granulomatous disease (CGD) is a rare
immunodeficiency affecting about 1 in 200,000 to 1 in 250,000
life births in Europe per year (4). Statistically, every CGD patient
though under prophylactic treatment experiences 0.71 episodes
of infection per year including surgical removal of inflamed tissue
once in 5 years per patient (37). Therefore, primary-derived
patient material is extremely rare. Furthermore, inflammation in
CGD can be caused by various pathogens including Aspergillus,
Burkholderia, Nocardia, Serratia, and Staphylococcus (38). These
infections manifest most frequently in lung, but can also affect
liver, lymph nodes, bone, skin, and soft tissues (38). Furthermore,
hyperinfammation in CGD is also reported without detectable
pathogen (20). The heterogenity of the causes and the tissue
localization is amplified by the kinetics of inflammation. In
addition, taking the rarity of the disease and of infection episodes
into account, it is almost impossible to obtain homogeneous
sample collections of inflamed tissue samples from CGD
patients. Accordingly, the samples characterized here represent
the general heterogeneity of inflammatory manifestations.
Besides susceptibility to bacterial and fungal infection, chronic
hyper-inflammation leading to granuloma formation in internal
organs is a characteristic of CGD (39). Both processes are likely
linked through impaired ROS formation, concomitant impaired
neutrophil extracellular trap (NET) formation and impaired
pathogen killing, as well as the impaired NADPH oxidase-
dependent oxidation of PS in granulocytic membranes (30, 31,
40, 41).
On the one hand, in neutrophils of healthy individuals
NADPH oxidase-derived ROS was reported to be essential for
PS oxidation and exposure during phorbol 12-myristate 13-
acetate (PMA)-induced cell death (42). Fernandez-Boyanapalli
et al., hypothesized that in CGD impaired PS exposure on
dying cells results in defective macrophage programming to
efferocytosing alternatively-activated macrophages, which in
consequence could lead to inefficient clearance of the infection
site from dying neutrophils and to enhanced inflammation (32).
The inefficient efferocytotic murine macrophage activity can be
reversed by IL-4 (32). On the other hand, in the zymosan-induced
peritonitis model in CGD mice, the percent of neutrophils
exposing PS was only slightly diminished compared to the
percentage in WT mice (43). Ex vivo, PS exposure by human
CGD granulocytes was reported upon spontaneous apoptosis
after 24 h of culture (31). In a review, a potential involvement
of cytosolic cytochrome C in lipid oxidation in apoptotic cells
was discussed (44). Such a mechanism potentially can explain the
observed PS oxidation observed in vivo in CGD.
Therefore, we propose that in CGD the crucial positive-
feedback loop consisting of the secretion of anti-inflammatory
IL-4 by macrophages does not take place, and pro-inflammatory
M1 macrophages cannot develop into anti-inflammatory M2a
macrophages, as this step requires exposure to anti-inflammatory
cytokines such as IL-4 and IL-13 (45, 46). To our knowledge,
no data regarding the cytokine expression in human primary-
derived inflamed CGD patient tissues have been reported so far.
Our results support this hypothesis by showing high levels
of IL-18 in chronically inflamed CGD tissue, while IL-6 was
dominating in acute phase of inflammation in CGD tissue,
most likely synthesized by granulocytes as most frequent
cell population in this tissue type (Figures 1A,D). In our
hands, IL-18 was released in high quantity by ex vivo primed
pro-inflammatory M1 macrophages, with CGD macrophages
differing from healthy controls only in absolute values of three
cytokines (Table 2) and in one surface marker (Table 1). This
is in contrast to the report on human CGD macrophages that
were described to show impaired production of IL-6, IFN-γ,
IL-12p70, IL-13, MCP-1, and MIP-1β, and increased secretion
of IL-10 (47). Likely, these differences can be attributed to the
fact that these latter data were obtained from monocyte-derived
macrophages from CGD patients receiving anti-inflammatory
and immunosuppressive treatment, e.g. corticosteroids. In our
analysis however, treatment with corticosteroids was an exclusion
criterion, as we wanted to exclude potential bias caused by
this treatment.
In three CGD tissue samples with inflammation persisting
for 2, 4, and for 6 weeks, we could detect IL-18, indicating the
persistence of IL-18 releasing cells. In inflamed CGD lymph node
tissue, macrophages were one source of IL-18 secretion. The
presence of macrophages in our CGD chronically inflamed tissue
is in line with the histological description of granulomas in CGD
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colitis (48). In murine X-CGD, the presence of pro-inflammatory
M1 macrophages has been reported, whilst WT mice showed the
presence of anti-inflammatory M2 macrophages (32, 33). Our ex
vivo experiments however clearly showed that CGDmacrophages
have the capacity to acquire all priming activities, provided they
are exposed to the appropriate stimuli, and that withdrawal of
M1 priming stimulus weakens their pro-inflammatory activity.
Hence, in inflamed CGD lymph node tissue, the persistence of
IL-18 secreting macrophages might be explained by a persisting
local microenvironment that keeps macrophages in M1 state and
leads to a persistent pro-inflammatory milieu.
IL-18, originally called IFN-γ inducing factor, is known to
enhance the secretion of IFN-γ from NK cells and CD4+
T helper 1 lymphocytes (49). It has been shown that in
combination with IL-15, IL-12, or with allergens IL-18 enhances,
or synergistically induces the production of IFN-γ in cord blood
mononuclear cells (50) or in NK cells (51). IFN-γ in turn may
prime macrophages to pro-inflammatory M1 phenotype when
combined with bacterial LPS (28). Indeed, we found increased
levels of IFN-γ in chronically inflamed lymph node tissue
by immunohistochemistry and cytokine quantification. Further
investigation is needed to prove that signaling emerging from IL-
18 and IFN-γ secreting cells build a paracrine signaling loop in
vivo. We were however unable to formally prove the presence
of IFN-γ releasing NK and/or T cells in the limited amount of
samples analyzed. The initial trigger for inflammation would be
an infectious organism or an infammasome stimulus, leading
to neutrophil recruitment and persistent inflammatory cytokine
secretion by the latter in the absence of NET formation. Tissue
macrophages would thus be primed into M1 pro-inflammatory
state without the possibility to return into neutral M0, or anti-
inflammatory M2a state, leading to increased IL-18 secretion.
On the one hand, a hypothetical IL-18 and IFN-γ signaling loop
could contribute to attraction of NK and/or T-cells and to an
increased IFN-γ production. This scenario is supported by the
fact, that clinically CGD patients might develop macrophage
activation syndrome leading to hemophagocytosis, similar to
hereditary hemophagocytic lymphohistiocytosis (52, 53). On the
other hand, IFN-γ has been used for years in many patients to
reduce infectious triggers for inflammation, with no evidence
of increased hyper-inflammatory complications. Therefore, it is
likely that IL-18 and IFN-γ axis is one out of several factors
potentially contributing to hyperinflammation in CGD.
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Figure S1 | Cytokine and chemokine levels quantified in inflamed lymph node vs.
in control lymph node tissue. In primary derived control lymph node tissue (B) and
in a chronically inflamed lymph node tissue of a CGD patient (A), signaling
molecules were quantified by Multiplex immunoassay. Results are given in pg/ml
of local undiluted concentrations. Tissue types and duration of inflammation at the
time of the analysis are indicated.
Figure S2 | Hematoxylin and eosin (H&E) staining. Inflamed lymph node tissue of
a CGD patient with inflammation persisting for 6 weeks was paraffin-embedded.
Sections of embedded lymph node tissue were stained with H&E according to
standard protocol as described recently (54). Images were then analyzed with a
bright field microscope (Axiovert S100TV, Carl Zeiss Vision Swiss AG, Feldbach,
Switzerland). Magnification is indicated.
Figure S3 | Immunofluorescence microscopy analysis of lymph node tissue of a
CGD patient with inflammation persisting for 6 weeks. Paraffin embedded lymph
node tissue section was dewaxed and double stained for IL-18 and CD68 and
DAPI. Immunofluorescence signal of IL-18 (FITC) was amplified by tertiary staining
with an anti-FITC Alexa488 antibody. CD68 is visualized by Cy3. Individual
pictures detecting DAPI (C), IL-18 (B) and CD68 (Cy3) (A) are shown. Merged
picture is shown in Figure 2A Scale bar: 50µm.
Figure S4 | Surface marker presentation (A) CD86, (B) CD209, (C) CD206, (D)
Mer and (E) CD163, on healthy control and CGD macrophages upon ex vivo
priming for 24 h. Blood monocyte-derived macrophages of CGD patients and of
healthy controls were primed to macrophage subpopulations for 24 h and
analyzed by flow cytometry analysis. Surface marker presentation is expressed as
mean fluorescence intensities of gated positive populations ± standard error of
the mean. N = 4, ∗p < 0.05, striped box-plots, CGD; empty box-plots, control.
Values are given in Table 1.
Figure S5 | Cytokine/chemokine secretion of CGD blood monocyte derived
macrophages compared to control upon 24 h priming. Blood monocyte derived
macrophages of CGD patients and of healthy controls were primed for 24 h and
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cytokine/chemokine concentrations in cell culture supernatants were quantified by
immunoassay. (A) IL-18, (B) IL-12p70, (C) IL-13, (D) IL-22, (E) IFN-γ, (F) IL-6, (G)
TNFα, (H) IL-5, (I) IL-4, (J) MDC, (K) GM-CSF, (L) G-CSF, (M) IL-1β.
Concentrations are expressed in Box-plot diagrams representing maximum
values, means, minimum values in pg/ml and statistical analyses of CGD vs.
controls. Striped box-plots, CGD; empty box-plots, control. N = 4, ∗p < 0.05,
n.d., not done as cytokines were utilized for cell stimulation. ∗p < 0.05. Values are
given in Table 2.
Figure S6 | Similar cytokine secretion of 24 h primed CGD macrophage
subpopulations followed by additional 72 h priming compared to healthy control
macrophages. Monocyte-derived macrophages of CGD patients and healthy
controls remained unstimulated (M0) or were primed to M1, M2a, or M2c followed
by additional 72 h either unstimulated (M0) or primed to M1, M2a, or M2c as
described. Cytokines released into the supernatants were quantified by
immunoassay. IL-18, MDC and GM-CSF are shown in Figure 3. (A) IL-12p70, (B)
IL-13, (C) IL-22, (D) IFN-γ, (E) IL-6, (F) TNFα, (G) IL-5, (H) IL-4, (I) G-CSF, (J)
IL-1β, (K) IL-23, (L) IL-9. Box-plot diagrams representing maximum values, means
and minimum values of CGD vs. controls are shown. striped box-plots, CGD;
empty box-plots, control. N = 3, n.d., not done as cytokines were utilized for
cell stimulation.
Table S1 | Cellular composition of analyzed primary derived CGD patient
tissue samples.
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